ClinicalTrials.gov
public full text
Public Domain
Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia
The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)#1336894
- Treatment of Patients With Anxiety Disorder (0777-022)#860778
- Study of Vilazodone to Treat Social Anxiety Disorder#1112746
- Social Safety Learning in the Brain Oxytocin System#968774
- GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)#834177
Record · ID 1498516
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive